Search:
Climacteric Editorial Board
Editor-in-Chief

Rod Baber is the immediate Past President and an Honorary Member of The International Menopause Society and Clinical Professor of Obstetrics and Gynaecology at Sydney Medical School, The University of Sydney.

He is a past President and Life member of The Australasian Menopause Society, a fellow of both The Royal College of Obstetricians and Gynaecologists and The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

He is an associate editor of The ANZ Journal of Obstetrics and Gynaecology.

He is head of The Menopause and Menstrual disorders unit at The Royal North Shore Hospital in Sydney as well as conducting a private clinical practice in obstetrics and gynaecology in Sydney.

He has had a career long interest in reproductive endocrinology, is widely published and is a regular speaker at national and international meetings.

Associate Editors
Peter Chedraui

Peter Chedraui  is an Obstetrician and Gynecologist, Associate professor  and Director of the Institute of  Biomedicine of the Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador.

He is Past President of the Ecuadorian Climacteric and Menopause Society, member of several international scientific society boards of which he has served two full periods for the International Menopause Society. 

His field of expertise is women's health, focused specifically on the menopause and its effect on weight, inflammation and the metabolism of ageing women, endorsed by more than 150 peer reviewed publications, many of which are part of a joint effort of a Latin American scientific network.

 

Tim Hillard

Tim Hillard is a Consultant Obstetrician & Gynaecologist at Poole Hospital, Dorset, UK. He graduated from Southampton University and subsequently worked at King's College Hospital, London where he  developed his interest in menopause and completed his MD on transdermal HRT and osteoporosis. He runs one of the few specialist menopause clinics in the South of England outside London and also heads a busy uro-gynaecology department.

He is a past Chairman and current trustee of the British Menopause Society. He is the immediate past secretary of the British Uro-gynaecology Society and is a patron of the Daisy network (a UK charity for women with premature ovarian insufficiency). He has lectured and published widely on various aspects of the menopause and uro-gynaecology.

James H Pickar

James H. Pickar is a fellow of the American College of Obstetrics and Gynecology and an Adjunct Associate Professor of Obstetrics and Gynecology at Columbia University College of Physicians and Surgeons.  

He has over 80 publications, is a Senior Editorial Advisor for Maturitas, and serves as a reviewer for multiple scientific journals.  He has also served on the board of the International Menopause Society and the Scientific Advisory Board of the International Symposium on Hormonal Carcinogenesis.  

Dr. Pickar was the 2013 recipient of the NAMS/Thomas B. Clarkson Outstanding Clinical & Basic Science Research Award and is a member of numerous professional and scientific organizations.

Tevfik Yoldemir

Tevfik Yoldemir is Professor of Obstetrics and Gynaecology at the Medical School of Marmara University, Istanbul, Turkey. He is a member of the Turkish Menopause and Osteoporosis Society, Turkish Urogynecology and Pelvic Reconstructive Surgery Association, Turkish Society of Reproductive Medicine, Pelvic Pain and Endometriosis Association and the Gynecologic and Obstetric Ultrasonography Association.

He is a member of the editorial board of the Marmara Medical Journal and he is the medical director of ART Unit and a full-time consultant in obstetrics and gynaecology clinic at the Marmara University Hospital in Istanbul.

His fields of interest are reproductive endocrinology, assisted reproductive technologies, endometriosis surgery, minimally invasive gynecologic surgery, pelvic floor reconstruction.

Qi Yu

Qi YU is the president of the Chinese Menopause society and the clinical professor of Reproductive Endocrinology in Peking Union Medical College Hospital. 

He is now the Deputy Director of the O&G Dept. in PUMC hospital and the Director of the assistant reproductive center.

He is the Editorial board member of Chinese Journal of Obstetrics and Gynecology, Chinese Journal of Osteoporosis and Bone Mineral Disease, Journal of Reproductive Medicine, Chinese Journal of Clinical Obstetrics and Gynecology, Journal of Practical Obstetrics and Gynecology, Chinese Journal of Practical Gynecology and Obstetrics.

He is experienced in diagnosis and treatment of gynecological endocrinology diseases with abundant publications and served as a regular speaker in this field.

Editorial Board
Professor Camil Castelo-Branco, MD, PhD (Spain)

Professor of Gynecology & Obstetrics, University of Barcelona; Senior Consultant Physician, Clinic Institute of Gynecology, Obstetrics & Neonatology; Hospital Clínic, Barcelona, Spain
Professor Castelo-Branco has disclosed that he is a recipient of research/grant funding from, is a consultant/advisor to and is a member of the speakers’ bureaux for: Amgen (Sp), Servier (Sp), Pierre-Fabre (Sp), Schering Plough (Sp), Isdin, Esteve, Eli Lilly and Daiichi Sankyo.

Mr Farook Al-Azzawi, MA(Cantab), PhD, FRCOG (United Kingdom)
Consultant Gynaecologist, Leicester Royal Infirmary, Leicester, UK
Mr Al-Azzawi has disclosed that he has received educational grants and sponsorship funding to attend meetings on behalf of Procter & Gamble, Servier, Solvay and Wyeth
Dr Peter Chedraui (Ecuador)
Professor Rod J Baber, MB BS, BPharm, FRCOG, FRANZCOG (Australia)

Clinical Professor of Obstetrics and Gynaecology, Sydney Medical School (North), The University of Sydney, Australia
Professor Baber has disclosed that, via hospital and university administered trust accounts, he has received research grants from Wyeth, Novartis, Organon, Upjohn, Bayer Schering, Proctor & Gamble, Pfizer and Novogen. He has served on speakers’ bureaux for Wyeth, Organon, Bayer Schering and Novo Nordisk. He has served on medical advisory boards for Servier and Wyeth. He currently holds no positions on medical advisory boards or speakers’ bureaux.

Dr A Collins, PhD (Sweden)

Associate Professor at the Section of Psychology, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
Professor Collins has no conflict of interest or disclosures.

Professor Robin Bell (Australia)
Professor Susan R Davis, MB BS, FRACP, PhD (Australia)

Department of Medicine, Central and Eastern Clinical School, Monash University, Prahran, Australia
Professor Davis has disclosed that she is a consultant to Procter & Gamble Pharmaceuticals, Bohringer Ingleheim and Acrux Pty Ltd, has research grant support from Bayer Schering, BioSante, Astra Zenica, Procter & Gamble and has received honoraria as a speaker for Organon Australia (now Pfizer).

Professor Mark P Brincat (Malta)
Dr Tobie J de Villiers, MBChB, MMed(O&G), MRCOG, FCOG(SA) (South Africa)

Consultant Gynaecologist, Panorama MediClinic and Department of Obstetrics & gynecology, University of Stellenbosch, Cape Town, South Africa
Dr de Villiers has disclosed that he is an investigator in clinical trials sponsored by MSD, Pfizer and Eli Lilly. He is presently on the advisory boards of Novartis(SA), Adcock Ingram, and Servier.

Professor Henry Burger, AO, MD, FRCP, FRACP, FCP (SA), FRCOG, FRANZCOG, FAA (Australia)

Emeritus Director, Prince Henry’s Institute of Medical Research, Consultant Endocrinologist, Jean Hailes Foundation for Women’s Health and Adjunct Professorial Fellow, Monash University, Melbourne, Australia.
Professor Burger has disclosed that he has served on Advisory Boards and/or acted as a symposium or dinner speaker for Schering Plough (formerly Organon), Novo Nordisk, Bayer Schering Pharma and Wyeth. He has no financial interests in these or other pharmaceutical companies.

Professor Edzard Ernst, MD, PhD, FMed Sci, FSB, FRCP, FRCP (Edin.) (United Kingdom)

Complementary Medicine, Peninsula Medical School, Exeter, UK
Professor Ernst has no conflict of interest to declare

Professor Richard Farmer, MB, PhD, FFPH, FFPM (United Kingdom)

Emeritus Professor of Epidemiology, University of Surrey, UK
Professor Farmer has disclosed that he is not in receipt of any research or consultancy funds. He has not accepted funding from the pharmaceutical industry for attending meetings for the past 3 years

Dr Anna Fenton, BHB, MBChB, PhD, FRACP (New Zealand)

Endocrinologist, Christchurch Women's Hospital, University of Otago School of Medicine, Christchurch, New Zealand
Dr Fenton has disclosed that she is or has been a recipient of research/grant funding from, a consultant/advisor to, and a member of the speakers’ bureaux for: Pfizer/Wyeth, Merck Sharpe and Dohme, Bayer Schering, Eli-Lilly, GlaxoSmithKline, Sanofi-Aventis and Novartis

Professor Marco Gambacciani (Italy)

Department of Obstetrics & Gynecology, Ospedale S. Chiara, University of Pisa, Pisa, Italy
Professor Gambacciani has no conflict of interest or disclosures

Professor Ulysse Gaspard, MD, PhD (Belgium)

Honorary Professor and Head, Department of Gynaecology, Sart Tilman University Hospital, University of Liege, Liege, Belgium; Senior Consultant Physician, University Clinics L.Brull, University of Liege, Belgium
Professor Gaspard has disclosed that he is a consultant/advisor to Mithra Pharmaceuticals

Professor Andrea Genazzani (Italy)
Professor Steven R Goldstein, MD (USA)
Professor of Obstetrics and Gynecology, New York University School of Medicine; Director of Gynecologic Ultrasound; Co-Director of Bone Densitometry, New York University Langone Medical Center, New York, USA
Professor Goldstein has disclosed that he is a Director for Sonosite, Inc., is on the Gyn Advisory Board for Amgen, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk, is a Consultant for Cook ObGyn and Phillips Ultrasound; and is a member of the speakers’ bureaux for Eli Lilly & Co, Procter & Gamble, and Warner Chilcott.
Professor Anne Gompel, MD, PhD (France)
Head of the Gynecology Endocrinology Unit, Hôtel-Dieu Hospital, Paris; Professor of Reproductive Endocrinology, Paris Descartes University, member of the INSERM UMRS 938 Saint Antoine CDR, Paris , France
Professor Gompel has disclosed that she is a recipient of research/grant funding from Novartis, HRA Pharma, Azko/Organon, Besins. She is a member of the Advisory board of EURAS HRT with an unrestricted grant from Bayer Schering. She is a consultant for Jerini-Shire Laboratory.
Professor Franco Guidozzi (South Africa)
Prof. Dr. med. Peyman Hadji (Germany)
Professor Victor W Henderson, MD, MS (USA)
Professor of Health Research & Policy (Epidemiology) and of Neurology & Neurological Science, Stanford University, Stanford, California, USA
Professor Henderson has disclosed that he is a recipient of research/grant funding from the National Institutes of Health.
Professor Marc LHermite, MD, PhD, DSci (Belgium)
Honorary Professor of the Université Libre de Bruxelles, Emeritus Head of Obstetrics & Gynecology Department of Brugmann Hospital, Brussels, Belgium
Professor L'Hermite has disclosed that he has been in the past the recipient of research/grant/congress travel funding from Besins, Farmitalia/Pharmacia, Organon, Sandoz, Solvay and Wyeth/Ayerst; and is presently a sporadic consultant to Besins.
Professor Rogerio A Lobo, MD, FACOG (USA)

Professor of Obstetrics and Gynecology, Columbia University, New York, New York
Professor Lobo has nothing to disclose

Professor Mary Ann Lumsden (United Kingdom)
Head of Section, Reproductive and Maternal Medicine, University of Glasgow, Royal Infirmary, Glasgow, UK
Professor Lumsden has nothing to disclose
Professor Alfred O Mueck, MD, PharmD, PhD (Germany)
Professor of Clinical Pharmacology and Experimental Endocrinology, Head of Centre of Women’s Health South Germany (BW), Medical Director of Department of Endocrinology and Menopause; University Women’s Hospital of Tuebingen, Germany
Professor Mueck has disclosed that he is a consultant/advisor to Bayer-Schering, Novartis, Novo Nordisk, Procter & Gamble, Schering-Plough/Merck Sharpe & Dohme and Solvay and is also a member of the speakers’ bureaux of these companies. He is a recipient of research/grant funding from Bayer-Schering, Dr.Kade Pharma, Novartis, Novo Nordisk and Schering-Plough/Merck Sharpe & Dohme.
Professor Rossella Nappi (Italy)
Research Center for Reproductive Medicine, Department of Morphological, Eidological & Clinical Sciences, University of Pavia, Pavia, Italy
Professor Nappi has disclosed that during the past 2 years, she has had financial relationships with Bayer-Schering Pharma, Boehringer Ingelheim, Merck-Theramex, Novo Nordisk, Procter & Gamble Pharmaceuticals, Schering-Plough/Organon.
Dr Santiago Palacios, MD, PhD (Spain)
Director of the Palacios Institute of Women’s Health, Madrid, Spain
Dr Palacios has disclosed that he is a recipient of research/grant funding from, is a consultant/advisor to, and/or is a lecturer for: Bayer-Schering, Novo Nordisk, Servier, Lilly, Daiichi-Sankyo, Sanofi-Aventis, MSD, Warner Chilcott Iberia, Pfizer-Wyeth, Amgen, Astra-Zeneca and Arkochim
Mr Nick Panay, BSc, MRCOG, MFSRH (United Kingdom)
Queen Charlotte’s & Chelsea Hospital, London, UK
Mr Panay has disclosed that he has acted in an advisory capacity, performed research and/or lectured on behalf of the following companies: Baxter, Bayer Schering, Eli Lilly, Galen, Janssen Cilag, Merck, Novo Nordisk, Novogen, Organon, Orion, Procter & Gamble, Se-cure, Servier, Shire, Solvay, Storz, and Wyeth.
Professor Faustino R Perez-Lopez (Spain)
Dr James H Pickar, MD, FACOG (USA)
Adjunct Associate Professor, Obstetrics and Gynecology, Columbia University Medical Center New York, NY, USA
Disclosures: Dr. Pickar has received consultant fees from Pfizer, Shionogi, Radius Health, and TherapeuticsMD; and has stock options with TherapeuticsMD.
Professor Amos Pines (Israel)

Specialist in Internal Medicine, working in the Tel-Aviv Medical Center, which is affiliated to the Tel-Aviv University School of Medicine
Professor Pines has disclosed that he has no conflict of interest, except for an indirect one, being a consultant for a local, Israeli distributor that represents about 20 international pharma companies with niche products in all fields of medicine

Professor JoAnn Pinkerton, MD (USA)
Professor of Obstetrics and Gynecology, Director, Midlife Health Division, University of Virginia, Charlottesville, Virginia, USA
Professor Pinkerton has disclosed that she is or has been Consultant/Advisory Board for Eli Lilly, Teva, Novo Nordisk, Amgen and Wyeth. She is currently involved in multicenter clinical trials as principal investigator for Wyeth and Pfizer. She serves on the Data Safety Monitoring Board for Boehringer Ingelheim. In addition, she serves as Past President and board member for the North American Menopause Society, is a member of the Council on Hormone Foundation for the Endocrine Society and a board member for the National Women’s Health Resource Center
Professor Giuseppe Rosano, MD, PhD (Italy)
Director, Centre for Clinical & Basic Research, IRCCS San Raffaele Roma, Rome, Italy
Professor Rosano has nothing to disclose
Professor Serge Rozenberg, MD (Belgium)
Professor of Obstetrics and Gynaecology, Université Libre de Bruxelles (Free University Brussels), Belgium
Professor Rozenberg has disclosed that he is a recipient of research grant/member of the advisory boards of Amgem, and Merck Sharpe & Dohme
Professor Hermann P G Schneider, MD, PhD, FRAM (Germany)
Emeritus Professor of Obstetrics & Gynecology, Department of Obstetrics & Gynecology, University of Muenster Medical School, Muenster, Germany
Professor Schneider has nothing to disclose
Dr Duru Shah (India)
Ex-Professor Obstetrics & Gynecology, Grant Medical College, Nowrosjee Wadia Maternity Hospital, University of Mumbai. Post Graduate Guide for Diplomate of National Board, Jaslok Hospital & Research Center, Mumbai, India
Dr Shah has disclosed that she is the Chairman of the Advisory Board for Wyeth Ltd. (subsidiary Pfizer inc.).
Professor Lee P Shulman (USA)
Dr John C Stevenson, MB BS, FRCP, FESC, MFSEM (United Kingdom)
Reader and Consultant Metabolic Physician/Honorary Principal Research Fellow, National Heart & Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
Dr Stevenson has disclosed that he is the recipient of research/grant funding from Schering Plough and Wyeth/Pfizer; is a consultant to Wyeth/Pfizer and lecturer for Bayer, Meda and Merck/Theramex
Professor John W W Studd, DSc, MD, FRCOG (United Kingdom)
Professor of Gynaecology, London PMS and Menopause Centre, London, UK
Professor Studd has disclosed that, since retiring from the NHS and the University 4 years ago, he has received no research funding but remains on the advisory board of Procter & Gamble
Dr David W Sturdee, MB BS, MD, DA, FRCOG (United Kingdom)
Consultant Gynecologist/Honorary Senior Clinical Lecturer, Solihull Hospital and University of Birmingham, UK
Dr Sturdee has disclosed that he is not currently in receipt of any research grant, but is a consultant/advisor to and is a member of the speakers’ bureaux for Amgen, Theramex, Procter & Gamble, Wyeth, Bayer Schering and Novo Nordisk
Dr D A Tan, MD, FPOGS, FPSREI, FPSGE (Philippines)
Head, Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, St. Luke's Medical Center, Quezon City, Philippines
Dr Tan has disclosed that he is currently advisor to Bayer Schering Pharma, has received research grants from Bayer Schering Pharma and Wyeth-Ayerst Pharmaceuticals, has received sponsorships to attend meetings from Bayer Schering Pharma, Eli Lilly, and AstraZeneca, and has given lectures for Bayer Schering Pharma, AstraZeneca, Eli Lilly, and Takeda.
Dr Lian G Ulrich, MD, Dip.Pharm Med. (UK), Gynaecologist and Obstetrician(DK) (Denmark)
Consultant at the Department of Obstetrics and Gynecology, Gynaecological Oncology Subgroup, Copenhagen University Hospital ‘Rigshospitalet’, Copenhagen, Denmark
Dr Ulrich has disclosed that she has received speaker’s fees and is a member of the Organon-Schering Plough-MSD Danish advisory board. She has also received speaker’s fees from Novo Nordisk and reimbursement of travelling expenses when speaking for Novo Nordisk in Europe. She and her husband own a small amount of stock in Novo Nordisk.
Professor Peter Van de Weijer, MD, PhD, DTMH (Netherlands)
Consultant Gynaecologist and Principal Tutor, Department of Obstetrics & Gynaecology, Gelre Teaching Hospital, University of Utrecht Medical School, Apeldoorn, the Netherlands
Professor Van de Weijer has disclosed that he is a member of the speakers’ bureau for Solvay
Professor Paulina Villaseca (Chile)
Associate Professor, Gynecologist, Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
Professor Villaseca has disclosed that she has lectured for Novartis and for Eli Lilly
Assoc. Prof. Amanda Vincent (Australia)
Consultant Endocrinologist, Menopause Unit, Southern Health, Monash Medical Centre, Clayton, Victoria, Australia; Senior Post-doctoral Research Fellow, Jean Hailes Foundation Clinical Research Unit, School of Public Health and Preventative Medicine, Monash University, Clayton, Victoria, Australia
Dr Vincent has disclosed that she is the recipient of research/grant funding from Organon and Ralph Lauren and has been a member of the speakers’ bureau for Organon. She has also received funding and speaker honorarium from Amgen.
Professor Bo von Schoultz, MD PhD (Sweden)
Professor, Department of Obstetrics and Gynecology, Karolinska University Hospital and Institute, Stockholm, Sweden
Professor von Schoultz has disclosed that he is the recipient of research/grant funding from Besins-Iscovesco, Procter & Gamble and Schaper & Brummer; is a consultant/lecturer for Bayer-Schering, Besins-Iscovesco, Novo Nordisk, Procter & Gamble and Schering-Plough.
Professor Tevfik Yoldemir (Turkey)
Marmara University School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Medicine and Infertility, Istanbul, Turkey.
Professor Yoldemir has no conflict of interest or disclosures
Professor Qi Yu (China)
Professor and Vice Director, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, People’s Republic of China
Dr Yu has disclosed that he is the recipient of sponsorship funding to attend meetings on behalf of and is a member of the speakers’ bureaux for Bayer, Merck, Wyeth, Solvay and MSD; he is a recipient of research/grant funding from Eli-Lilly, Merck and Daiichi Sankyo.
Dr Peter Alexandersen, MD (Denmark)

Center for Clinical and Basic Research (CCBR), Denmark
Dr Alexandersen has no conflict of interest or disclosures.